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A method to ensure that an analytical method will produce reliable and interpretable information about 
the sample must first be validated, making sure that the results can be trusted and traced. In this study, 
we propose to validate an analytical high performance liquid chromatography (HPLC) method for the 
quantitation of meloxicam loaded PEGylated nanocapsules(M-PEGNC). We performed a validation 
study, evaluated parameters including specificity, linearity, quantification limit, detection limit, accuracy, 
precision and robustness. PEGylated nanocapsules were prepared by interfacial deposition of preformed 
polymer, and the particle size, polydispersity index, zeta potential, pH value and encapsulation efficiency 
were characterized. The proposed HPLC method provides selective, linear results in the range of 
1.0-40.0 μg/mL; quantification and detection limits were 1.78 μg/mL and 0.59 μg/mL, respectively; 
relative standard deviation for repeatability was 1.35% and intermediate precision was 0.41% and 0.61% 
for analyst 1 and analyst 2, respectively; accuracy between 99.23 and 101.79%; robustness between 
97.13 and 98.45% for the quantification of M-PEGNC. Mean particle diameters were 261 ± 13 nm and 
249 ± 20 nm, polydispersity index was 0.15 ± 0.07 and 0.17 ± 0.06, pH values were 5.0 ± 0.2 and 5.2 ± 0.1, 
and zeta-potential values were -37.9 ± 3.2 mV e -31.8 ± 2.8 mV for M-PEGNC and placebo(B-PEGNC), 
respectively. In conclusion, the proposed analytical method is suitable for the quality control of M-PEGNC. 
Moreover, suspensions showed monomodal size distributions and low polydispersity index indicating 
high homogeneity of formulations with narrow size distributions, and appropriate pH and zeta potential. 
The extraction process was efficient for release of meloxicam from nanostructured systems.
Uniterms: High performance liquid chromatography/quantitative analysis. Meloxicam/determination. 
PEGylated nanocapsules/quality control. Nanoparticles. Poly(ethylene glycol).
Para se assegurar que um método analítico produzirá informação confiável e interpretável sobre a amostra 
este deve ser inicialmente validado, tornando claro que os resultados podem ser confiados e rastreados. 
Neste estudo, propomos validar um método de cromatografia líquida de alta eficiência (CLAE) para 
a quantificação do meloxicam encapsulado em nanocápsulas PEGuiladas (M-PEGNC). Efetuamos 
a validação, avaliando parâmetros de especificidade, linearidade, limite de quantificação, limite de 
detecção, exatidão, precisão e robustez. As nanocápsulas PEGuiladas foram preparadas por deposição 
interfacial do polímero pré-formado e caracterizaram-se o tamanho da partícula, índice de polidispersão, 
potencial zeta, pH e eficiência de encapsulação. O método de CLAE proposto fornece resultados 
seletivos e lineares na faixa de 1,0-40,0 mg/mL; limites de quantificação e detecção de 1,78 mg/mL e  
0,59 mg/mL, respectivamente; desvio padrão relativo para a repetibilidade de 1,35% e precisão 
intermediária de 0,41% e 0,61% para o analista 1 e analista 2, respectivamente; exatidão entre 99,23 
e 101,79%; robustez entre 97,13 e 98,45% para a quantificação de M-PEGNC. Os diâmetros médios 
das partículas foram 261 ± 13 nm e 249 ± 20 nm; índice de polidispersão de 0,15 ± 0,07 e 0,17 ± 0,06, 
valores de pH de 5,0 ± 0,2 e 5,2 ± 0,1 e valores do potencial zeta de -37,9 ± 3,2 mV e -31,8 ± 2,8 mV 
para o M-PEGNC e o placebo(B-PEGNC), respectivamente. Concluindo, o método analítico proposto 
é adequado para o controle de qualidade do M-PEGNC. Além disso, suspensões mostraram distribuição 
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de tamanho monomodal e baixo índice de polidispersão, indicando alta homogeneidade das formulações 
com distribuição estreita de tamanho, pH e potencial zeta apropriados. O processo de extração foi eficiente 
para a liberação do meloxicam dos sistemas nanoestruturados.
Unitermos: Cromatografia líquida de alta eficiência/análise quantitativa. Meloxicam/determinação. 
Nanocápsulas PEGuiladas/controle de qualidade. Nanopartículas. Poli(etileno glicol).
INTRODUCTION
B i o d e g r a d a b l e  p o l y m e r s ,  s u c h  a s  p o l y 
(ε-caprolactone) (PCL) and their copolymers diblocked 
or multiblocked with poly(ethylene glycol) (PEG), have 
been commonly used to form polymeric nanoparticles 
and to encapsulate a variety of therapeutic compounds 
(Chan et al., 2010; Plapied et al., 2011). Nanoparticles 
feature dimensions from one to hundreds of nanometers, 
and remarkable applications in biomedicine due to the 
unique way in which they interact with matter (Wagner 
et al., 2006; Kim, Rutka, Chan, 2010). However, several 
challenges hamper the use of nanoparticles in clinical 
practice, such as their uptake by the reticuloendothelial 
system (Knop et al., 2006). The addition of PEG to the 
surface of nanoparticles (PEGylation) can reduce many 
of these challenges. Furthermore, PEG is one of few 
polymers approved for internal use in humans by the FDA, 
which is an important consideration in developing new 
pharmaceutical formulations (USP-NF, 2013).
PEGylated nanoparticles increase the potential 
for drug delivery and targeting system, besides crossing 
the blood-brain barrier interacting with microvascular 
transport proteins. Also, PEG chains can create a barrier 
layer with the finality of camouflage the phagocytic 
cells, thus prolonging the circulation period in the blood 
(Owens III, Peppas, 2006; Grover, Hirani, Sutariya, 
2013; Rabanel, Hildgen, Banquy, 2014). Moreover, PEG 
provides a system with adequate stability in physiological 
media, which is useful to target tumoral and inflamed 
regions (Beduneau et al., 2007; Diaz-Lopez et al., 2010; 
Hervella et al., 2014). Accordingly, the nanoencapsulation 
of anti-inflammatory drugs is very promising for use as 
adjuvant treatment of various diseases. In this context, 
meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-
thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-
dioxide] is a nonsteroidal anti-inflammatory drug with 
analgesic and antipyretic effects that preferentially inhibits 
cyclooxygenase-2 (Megan, 2006). 
However, nanoencapsulation requires considerable 
quality control. The choice of an appropriate analytical 
methodology is crucial for efficient quality control of an 
active substance, as such, or in a certain pharmaceutical 
form (Ermer, 2001). In order to ensure that an analytical 
method will generate reliable and interpretable information 
about a sample, this method must first be validated, 
ensuring the reliability and traceability of results (Ribani 
et al., 2004). In fact, according to Brazilian legislation, 
an analytical methodology for analysis of a drug or 
pharmaceutical form should be validated when it is not 
described in pharmacopeias or official forms recognized 
by the National Health Surveillance Agency (ANVISA, 
2003). No previous data in the literature demonstrated the 
development and validation of a quantitative bioanalytical 
high-performance liquid chromatography (HPLC) method 
for the quantification of meloxicam-loaded PEGylated 
nanocapsules(M-PEGNC).
Moreover, experimental studies should ensure 
that the method meets the requirements of analytical 
applications, demonstrating the reliability of the 
results (ANVISA, 2003). The characterization of 
nanostructured materials is carried out by different 
methods. These methods are essential to determine the 
drug content incorporated into them. Some methods 
for the quantification of meloxicam in pharmaceutical 
forms by HPLC method are described in the literature 
(Zhang, Choi, 2008; Bandarkar, Vavia, 2009; Sahoo et 
al., 2014). However, there is no specific methodology for 
nanostructured systems containing meloxicam. Therefore, 
in this study, we revalidate the analytical HPLC method 
for quantitation of M-PEGNC prepared according to 
the interfacial deposition of preformed polymer. This 
method was validated according to the official guidelines 
(ANVISA, 2003; ICH, 2005).
MATERIAL AND METHODS
Reagents and chemicals
Meloxicam (Henrifarma® - Brazil). Caprylic/
capric triglyceride and polysorbate 80 (Delaware® 
- Brazil). Span 60® (sorbitan monostearate) (Sigma 
Aldrich® - USA). Polyethylene glycol 4000 (PEG) 
(Galena® – Brazil). Poly(ε-caprolactone) (PCL) (70000) 
(Sigma-Aldrich® - USA). HPLC-grade methanol 
(Sigma-Aldrich® - Venezuela). Milli-Q Water (Millipore 
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Corporation®). All other chemicals and solvents used 
were of analytical or pharmaceutical grade. All reagents 
were used as received.
Preparation of loaded PEGylated nanocapsules
M-PEGNC were prepared by interfacial deposition 
of preformed polymer according to Fessi et al. (1989). 
Meloxicam was dissolved in acetone with the polymer 
(PCL), the oil (caprylic/capric triglyceride) and sorbitan 
monostearate at 40 ºC. This organic phase was poured 
into an aqueous phase composed of polysorbate 80 and 
PEG under stirring, leading to the immediate formation 
of a milky dispersion. Lastly, the organic solvents 
were removed under vacuum, and the M-PEGNC was 
concentrated to 0.3 mg/mL (w/v) and a fixed volume 
of 25 mL. The placebo suspension (drug-unloaded 
B-PEGNC) was prepared as described above without 
adding meloxicam.
Physico-chemical characterization of loaded 
PEGNC
The particle size, polydispersity index and zeta 
potential of M-PEGNC and B-PEGNC were measured 
by photon correlation spectroscopy. Samples were diluted 
in Milli-Q water and the analysis was performed at 25 
ºC, using a Zetasizer® (Nanoseries, Malvern, UK). The 
pH values of the suspensions were determined using a 
Denver® (Ultrabasic) potentiometer. Each sample was 
analyzed in triplicate.
Extraction of meloxicam from the nanocapsules 
After preparation, several tests were performed 
for drug extraction from nanocapsules with change of 
solvents, ultrasound, agitation, heating and centrifugation 
time (Table I). The amount of meloxicam was determined 
by the straight-line equation of the standard curve 
obtained.
Encapsulation efficiency of M-PEGNC
The amount of the encapsulated drug was determined 
in the clear supernatant following separation of the 
M-PEGNC from the aqueous medium by a combined 
filtration and centrifugation technique. The meloxicam 
content in the M-PEGNC was calculated by the difference 
between the total and free estimated drug concentrations. 
Measurements were performed in triplicate for all 
prepared batches.
TABLE I - Altered parameters for drug extraction from the 
nanocapsules
Parameters Variations
Solvents (used alone or mixed 
in various proportions)
methanol 
acetonitrile 
ethanol 
tetrahydrofuran 
NaOH
Initial ultrasound time and after 
shaking
5 minutes 
10 minutes 
15 minutes 
20 minutes
Shaking time
30 minutes 
60 minutes
Centrifugation time
15 minutes 
20 minutes
Heating time
37 ºC e 40 ºC - 10 minutes 
37 ºC e 40 ºC - 15 minutes 
37 ºC e 40 ºC - 30 minutes
Chromatographic conditions and instruments
The assay was developed and validated on a Shimadzu 
LC system (Kyoto Japan), with an LC-20AT pump, SIL-
20A ht automatic injector, CTO-20AC column oven, SPD-
M20A photodiode array detector (PDA) and CBM-20A 
controller with LC solution software. Chromatographic 
separations were achieved using a Phenomenex® Luna 
C18 (250 x 4.6 mm, 5 μm) column. The mobile phase 
and diluent contained a mixture of methanol:aqueous 
phosphoric acid (1%, v/v) pH 2.5 (70:30 v/v), 1.0 mL/min 
flow, PDA detection at 360 nm (Zhang, Choi, 2008; Patel et 
al., 2011). The injection volume was 20 μL and the column 
temperature was set at 25 ºC.
Validation study
Parameters evaluated included specificity, linearity, 
quantification limit, detection limit, accuracy, precision 
and robustness.
System suitability
System suitability was evaluated by five replicate 
analyses of a meloxicam reference substance and sample at 
a concentration of 10.0 μg/mL. The parameters calculated 
were: number of theoretical plates, tailing factor and 
asymmetry.
Specificity
To assess the method specificity, a solution of 
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meloxicam reference chemical substance (RCS) and 
placebo (B-PEGNC) was prepared. All analyses were 
performed in triplicate. The purity of the chromatographic 
peak with respect to meloxicam was determined with the 
aid of PDA.
Linearity and range
Method linearity was evaluated through a calibration 
curve in the 1.0-40.0 μg/mL concentration range. An 
initial solution of meloxicam (1000 μg/mL) was prepared 
in a volumetric flask with methanol and 1 mL NaOH. 
This solution was diluted appropriately in the range 
from 1.0 to 40.0 μg/mL, with an average concentration 
of 10.0 μg/mL. The linear working range was obtained 
by plotting the area ratio of meloxicam as a function of 
the meloxicam concentration, and a least square linear 
regression analysis was conducted.
Quantification limit and detection limit
The quantification and detection limits were based 
on standard deviation of response and mean slope of three 
calibration curves. 
Precision and accuracy
The precision assay was investigated with respect to 
repeatability (intra-day) and intermediate precision (inter-
day). The repeatability was evaluated by assaying six 
determinations at a concentration of 10.0 μg/mL, during 
same day and under the same experimental conditions. 
The same analysis was performed on 3 different days to 
assess intermediate precision. Precision was expressed as 
% of relative standard deviation (RSD).
Accuracy was evaluated by the amount of 
meloxicam RCS. The study was performed by adding 
a known amount of meloxicam standard solution to 
sample solution, to obtain the final concentrations of 5.0, 
7.0, 10.0, 12.0 and 15.0 µg/mL. The experiments were 
repeated three times.
Robustness
Four analytical parameters were selected and small 
variations were induced in nominal values of the method. 
The parameters employed, as well as the variations 
introduced are shown in Table II.
An appropriate amount was transferred into an 
individual 10 mL volumetric flask, diluted to volume 
with diluents, and filtered through a 0.45 μm membrane 
filter (Millipore, Bedford, USA), obtaining the final 
concentration of 10.0 μg/mL of the active pharmaceutical 
ingredient. The concentrations of meloxicam presented in 
samples were determined from the standard curve.
RESULTS AND DISCUSSION
In this study, we developed a suspension that enables 
controlled release through nanocarriers. M-PEGNC 
consisting of an oily core stabilized with a PEG, 
M-PEGNC was characterized with respect to their 
mean particle diameter, polydispersity index, pH, zeta 
potential and encapsulation efficiency. Furthermore, the 
analytical HPLC method was validated for quantitation 
of M-PEGNC. In fact, nanostructured systems coated 
with polymers, such as PEG, can increase drug half-life 
in the blood circulation, prevent opsonizing proteins from 
adhering to the nanomaterial surface, and reduce rapid 
metabolism and clearance (Kim, Rutka, Chan, 2010; 
Bender et al., 2012).
Physico-chemical characterization of loaded PEG-
NC
We designed M-PEGNC based on a PCL and capric/
caprylic triglyceride materials known to be useful for 
the encapsulation of drugs (Jornada et al., 2012). In fact, 
PCL and PEG meet drug delivery device requirements 
of biodegradability, biocompatibility and absence of 
immunogenicity (Chan et al., 2010; Lepeltier, Bourgaux, 
Couvreur, 2014). M-PEGNC and B-PEGNC suspensions 
were prepared by interfacial deposition of preformed 
polymer and did not require subsequent purification. 
Both suspensions (M-PEGNC and B-PEGNC) were 
macroscopically homogeneous bluish-white opalescent 
liquids.
After preparation, the mean particle diameters 
(Z-average) were 261 ± 13 nm for M-PEGNC and 249 
± 20 nm for B-PEGNC (Figure 1). In fact, the mean 
particle sizes of nanocapsules prepared from pre-formed 
polymers are generally between 250 and 500 nm (Mora-
Huertas, Fessi, Elaissari, 2010). Furthermore, particle 
sizes smaller than 500 nm and composed of biocompatible 
materials are very important characteristics for therapeutic 
applications (Bender et al., 2012). However, the size of 
TABLE II - Analytical parameters and variations to evaluate 
the robustness of the chromatographic method for meloxicam 
quantification
Parameter Variation
Mobile phase flow rate(mL min-1) 1.2 0.8
Column supplier Phenomenex Gemini
Column temperature (ºC) 25 30
Mobile phase pH 2.3 2.8
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individual particles tested for drug delivery of therapeutic 
and imaging agents may range from 2 to 1000 nm 
(Plapied et al., 2011). According to Kreuter (2014), for 
pharmaceutical purposes nanoparticles ranging in size 
from 1 to 1000 nm consist of macromolecular materials 
in which the active principle is dissolved, entrapped, or 
encapsulated, or to which the active principle is adsorbed 
or attached.
The suspensions showed monomodal  s ize 
distributions and a polydispersity index of 0.15 ± 0.07 for 
M-PEGNC and 0.17 ± 0.06 for B-PEGNC, indicating that 
the formulations were highly homogeneous with narrow 
size distributions. Accordingly, nanoparticles produced 
by the nanoprecipitation method feature a well-defined 
size and are characterized by an instantaneously formed 
narrow distribution (Rao, Geckeler, 2011). The pH values 
were 5.0 ± 0.2 for M-PEGNC and 5.2 ± 0.1 for B-PEGNC. 
FIGURE 1 - Particle diameters of placebo and M-PEGNC.(A) M-PEGNC; (B) Placebo(B-PEGNC).
In general, pH values of nanocapsule dispersion are 
within a range of 3.0–7.5 when nanoprecipitation occurs. 
Furthermore, the medium pH may play an important role 
in relation to the size of the nanoparticles as well as their 
biodistribution (Mora-Huertas, Fessi, Elaissari, 2010). 
Zeta potential is an indicator of surface charge, 
which determines particle stability in dispersion (Win, 
Feng, 2005). The zeta-potential values were -37.9 ± 3.2 
mV e -31.8 ± 2.8 mV, for M-PEGNC and B-PEGNC 
respectively (Figure 2). The zeta-potential of nanocapsules 
depends mainly on the chemical nature of polymer and 
stabilizing agent, and medium pH (Mora-Huertas, Fessi, 
Elaissari, 2010). Physicochemical analyses demonstrated 
that suspensions showed homogeneity with a narrow 
distribution of mean diameter and low polydispersity. 
Additionally, suspensions demonstrated appropriate zeta 
potential and pH. According to a study by Win and Feng 
FIGURE 2 - Zeta-potential placebo and M-PEGNC. (A) Placebo B-PEGNC; (B) M-PEGNC.
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(2005), stable nanoparticules were found in a state of 
dispersion, with high absolute values of zeta potential and 
negative surface charges.
Extraction of M-PEGNC
Several tests were performed for the extraction of 
meloxicam from the nanocapsules. The best way to mine 
meloxicam in several tests was by adding nanocapsules 
in suspension in a volumetric flask with 3 mL methanol 
and subjecting it to ultrasound for 15 minutes, followed 
by heating at 40 °C for another 15 minutes. Next this 
solution was subjected to shaking for 60 minutes. To this 
solution were added 1 mL NaOH 0.5 M methanolic and 
6 mL tetrahydrofuran and it was subjected to ultrasound 
for another 15 minutes. Then, this solution was added in 
another volumetric flask and supplemented with methanol. 
This solution was centrifuged at 4000 rpm for 10 minutes 
in order to extract the drug present in the nanostructures. 
The changes in some method parameters, such as solvents, 
ultrasound, agitation, heating and centrifugation during the 
optimization of drug extraction process from nanocapsules 
were rejected for different reasons, e.g. precipitation of 
the polymer or drug degradation. The extraction process 
proved to be efficient and the proposed method was 
simple and efficient for quantification and quality control 
of M-PEGNC.
Quantification of M-PEGNC
The extraction method described above was used to 
determine meloxicam in nanocapsules. After extraction, 
the samples were filtered and then analyzed by HPLC, 
using the previously validated method. The theoretical 
concentration obtained was 10.0 mg/mL.
Encapsulation efficiency of M-PEGNC
The calculation of the difference between total 
amount of drug present in the suspension and free drug 
found in the supernatant after centrifugation was used 
to check the encapsulation efficiency of M-PEGNC. 
The encapsulation efficiency was close to 99% for all 
batches. Agreement about nanoprecipitaton methods 
generated good results for nanocapsule encapsulation 
(80% or more). In addition, drug encapsulation efficiency 
is determined by different factors, such as chemical 
nature and polarity of the drug (Mora-Huertas, Fessi, 
Elaissari, 2010).
Validation method
System suitability
To obtain the best chromatographic method, 
the mobile phase containing methanol and aqueous 
phosphoric acid (70:30 v/v, pH 2.5) was utilized to provide 
adequate peak and satisfactory results. A 250 mm length 
octylsilane column was able to obtain a resolution and 
peak asymmetry and short analysis time.
Specificity
The chromatograms obtained with the specificity 
test (Figure 3), showed that none of the formulation 
excipients eluted in the same retention time as the 
FIGURE 3 - Chromatograms corresponding to: (A) solution of meloxicam reference substance; (B) M-PEGNC; (C) Placebo 
(B-PEGNC).
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TABLE III - Analytical parameters and variations to evaluate the 
repeatability of the chromatographic method for meloxicam 
quantification
Day n
Repeatability  
Content of the sample (%)
Analyst 1
1
1 98.90
2 96.41
3 95.51
4 96.43
5 95.90
6 95.33
Mean (%) ± SD 96.41 ± 1.30
RSD (%) 1.35
*p<0,05; SD – standard deviation; RSD – relative standard 
deviation.
meloxicam. Therefore none of the excipients interfered 
in the quantitative analysis of the meloxicam.  
Linearity and range
Linearity corresponds to the abili ty of the 
methodology to demonstrate that values obtained are 
directly proportional to the drug concentration in the 
sample within a specified range. In fact, it is recommended 
that it be composed of at least five concentration levels 
within a range corresponding to at least 80 to 120 % of 
the working concentration (ANVISA, 2003; ICH, 2005).
Linearity was observed over the concentration 
range of 1.0 - 40.0 μg/Ml (Figure 4), with a correlation 
coefficient of r = 1.0000 according to the criteria 
established for r = 0.99 and the linear regression equation 
y = 72888x –2717 (where, x is concentration and y is the 
peak absolute area). Assay validity was verified by means 
of the ANOVA. According to the statistical data, there is 
a linear relationship between the variables and there is 
no deviation from linearity (p<0.05). It was shown that it 
could be used for interpolation of the experimental values, 
aiming at quantitative determination of this substance. 
Quantification and detection limits were 1.78 μg/mL and 
0.59 μg/mL respectively, showing method sensibility.
Precision and accuracy
Precision is the scattering of results among different 
studies, repeated from the same sample, or samples of 
similar patterns under defined conditions (ANVISA, 
2003).
Method precision was evaluated as repeatability 
and intermediate precision and was expressed as RSD %. 
Mean results were 1.35% and 0.51% of RSD respectively. 
The limit is RSD maximum of 2.0% (USP, 2012).
Experimental results for intermediate precision were 
evaluated statistically by analysis of variance (ANOVA) in 
order to determine whether there is a significant difference 
FIGURE 4 - Graphic representation of the average standard 
curve reference chemical substance(RCS) meloxicam.
in the values obtained on different days. As shown in 
Tables III and IV, the value obtained for calculated F is 
lower than the tabulated value F, indicating no significant 
difference between the results for p<0.05.
From RSD values obtained, it can be seen that the 
developed method provides an accurate determination 
to show when it was performed on different days and by 
different analysts, and adequate repeatability for analysis 
on the same day.
The test was carried out accurately by retrieving the 
amounts of RCS added to the sample, obtaining a mean 
value of 100.25% (Table V). The recommended value 
for different levels of concentration must be in the range 
of 98.0% to 102.0% (ANVISA, 2003; ICH, 2005). The 
method showed adequate strength when subjected to small 
variations in the parameters established. 
Robustness
After variation of some parameters of the method 
proposed, these variations were not able to significantly 
change the meloxicam content in the sample, average 
levels of meloxicam ranging from 97.13 to 98.45%.
The validation methods ensure credibility during 
routine use and, sometimes, they are referred to as the 
process that provides documented evidence of method 
(USP, 1999). In addition, ICH, ANVISA and other 
agencies require the validation of analytical methods as a 
key requirement in the accreditation for quality assurance 
and demonstration of technical competence (ANVISA, 
2003; ICH, 2005). The proposed liquid chromatography 
method provides selective, linear, precise, accurate and 
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robust results. Furthermore, the method is linear over a 
wide range, inexpensive and utilizes a mobile phase that 
can be easily prepared. Moreover, some studies indicated 
that use of methanol as an organic solvent is less harmful 
for the environment and it is even considered favorable 
when a methanol-water mixture is used (Capello, Fischer, 
Hungerbuhler, 2007). A 250 mm length octylsilane column 
was able to obtain a resolution, peak asymmetry and short 
analysis time. All these factors make this method suitable 
for quantification of M-PEGNC.
CONCLUSION
In conclusion, the suspensions showed mean 
particle sizes according to the literature, monomodal size 
distributions and low polydispersity index indicating 
highly homogeneous formulations with narrow size 
distributions and appropriate pH and zeta potential. The 
extraction process proved to be efficient for the release 
of meloxicam nanostructured systems. The proposed 
liquid chromatography method provides selective, linear, 
precise, accurate and robust results for the quantification of 
M-PEGNC. The proposed method is suitable to determine 
meloxicam in the quality control for M-PEGNC.
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TABLE IV - Analytical parameters and variations to evaluate the intermediate precision of the chromatographic method for 
meloxicam quantification
Day n
Intermediate precision 
Content of the sample (%)
Mean ± SD RSD (%)
Analyst 1 Analyst 2
1
1 97.11 96.78
2 97.12 97.69 97.15 ± 0.45 0.47
3 97.65 96.56
2
1 97.18 97.72
2 96.94 96.70 97.00 ± 0.44 0.45
3 96.44 97.03
3
1 97.14 98.32
2 97.27 97.77 97.42 ± 0.44 0.45
3 97.84 97.36
Mean Overall (%) ± SD 97.26 ± 0.49
RSD Overall (%) 0.51
ANOVA F calculated F tabulated*
Between days 3.13 3.68
*p<0,05; SD – standard deviation; RSD – relative standard deviation.
TABLE V - Experimental values obtained for the accuracy test
Samples Final concentration (µg/mL)
Average number of RCS recovered*
(µg/mL) (% +SD)
R1 7 6.95 99.23 ± 0.12
R2 10 10.07 100.70 ± 0.29
R3 12 12.41 99.30 ± 0.12
R4 15 15.27 101.79 ± 0.47
*average of 3 determinations; SD – standard deviation.
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